Immunoproteomic Analysis of Potentially Severe Non‐Graft‐Versus‐Host Disease Hepatitis After Allogenic Bone Marrow Transplantation

The development of potentially severe non‐graft‐versus‐host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported after bone marrow transplantation (BMT). The aim of this study was to better characterize this form of hepatitis, particularly through the identification of au...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2013-02, Vol.57 (2), p.689-699
Hauptverfasser: Beleoken, Elvire, Sobesky, Rodolphe, Le Caer, Jean‐Pierre, Le Naour, François, Sebagh, Mylène, Moniaux, Nicolas, Roche, Bruno, Mustafa, Mohammad Zahid, Guettier, Catherine, Johanet, Catherine, Samuel, Didier, Bouhris, Jean‐Henri, Duclos‐Vallee, Jean‐Charles, Ballot, Eric
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 699
container_issue 2
container_start_page 689
container_title Hepatology (Baltimore, Md.)
container_volume 57
creator Beleoken, Elvire
Sobesky, Rodolphe
Le Caer, Jean‐Pierre
Le Naour, François
Sebagh, Mylène
Moniaux, Nicolas
Roche, Bruno
Mustafa, Mohammad Zahid
Guettier, Catherine
Johanet, Catherine
Samuel, Didier
Bouhris, Jean‐Henri
Duclos‐Vallee, Jean‐Charles
Ballot, Eric
description The development of potentially severe non‐graft‐versus‐host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported after bone marrow transplantation (BMT). The aim of this study was to better characterize this form of hepatitis, particularly through the identification of autoantigens recognized by patient sera. Five patients who received an allogeneic BMT for the treatment of hematological diseases developed liver dysfunction with histological features suggestive of AIH. Before and during the onset of hepatic dysfunction, sera were tested on immunoblottings performed with cytosolic, microsomal, mitochondrial, and nuclear proteins from rat liver homogenate and resolved by two‐dimensional electrophoresis. Antigenic targets were identified by mass spectrometry. During the year that followed BMT, all patients presented with GVHD. Acute hepatitis then occurred after the withdrawal, or during the tapering, of immunosuppressive therapy. At that time, no patients had a history of liver toxic drug absorption, patent viral infection, or any histopathological findings consistent with GVHD. Immunoreactive spots stained by sera collected at the time of hepatic dysfunction were more numerous and more intensely expressed than those stained by sera collected before. Considerable patient‐dependent pattern heterogeneity was observed. Among the 259 spots stained exclusively by sera collected at the time of hepatitis, a total of 240 spots were identified, corresponding to 103 different proteins. Twelve of them were recognized by sera from 3 patients. Conclusions: This is the first immunological description of potentially severe non‐GVHD hepatitis occurring after BMT, determined using a proteomic approach and enabling a discussion of the mechanisms that transform an alloimmune reaction into an autoimmune response. Any decision to withdraw immunosuppression after allogeneic BMT should be made with caution. (HEPATOLOGY 2013)
doi_str_mv 10.1002/hep.26024
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00798265v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2883105131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4224-9e80f8bd1b9ed84527a332c2a5366a41b269ab5dc576930a6830c587a8d7113c3</originalsourceid><addsrcrecordid>eNp1kctu1TAQhi1ERQ8tC14AWWLFIq0vudjLUEpT6RQq9bK1nGRCUzl2ajutzo4lS56RJ8HllLJiNaNfnz5p5kfoLSUHlBB2eAPzASsJy1-gFS1YlXFekJdoRVhFMkm53EWvQ7glhMiciVdolzFJU1ys0I_TaVqsm72L4Kaxw7XVZhPGgN2Az1No46iN2eALuAcP-Iuzv77_PPF6iGlegw9LSEvjQsSfxgA6AG5g1nGMyVEPETyujXHfwCb5R2cBn2nv3QO-9NqG2WgbE-zsPtoZtAnw5mnuoavPx5dHTbb-enJ6VK-zLmcszyQIMoi2p62EXuTpWM0565gueFnqnLaslLot-q6oSsmJLgUnXSEqLfoqndzxPfRh673RRs1-nLTfKKdH1dRr9ZgRUknByuKeJvb9lk3vuVsgRHXrFp8eFBRlIqdUcsr-GTvvQvAwPGspUY_9qNSP-tNPYt89GZd2gv6Z_FtIAg63wMNoYPN_k2qOz7fK351onRI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1284119312</pqid></control><display><type>article</type><title>Immunoproteomic Analysis of Potentially Severe Non‐Graft‐Versus‐Host Disease Hepatitis After Allogenic Bone Marrow Transplantation</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Beleoken, Elvire ; Sobesky, Rodolphe ; Le Caer, Jean‐Pierre ; Le Naour, François ; Sebagh, Mylène ; Moniaux, Nicolas ; Roche, Bruno ; Mustafa, Mohammad Zahid ; Guettier, Catherine ; Johanet, Catherine ; Samuel, Didier ; Bouhris, Jean‐Henri ; Duclos‐Vallee, Jean‐Charles ; Ballot, Eric</creator><creatorcontrib>Beleoken, Elvire ; Sobesky, Rodolphe ; Le Caer, Jean‐Pierre ; Le Naour, François ; Sebagh, Mylène ; Moniaux, Nicolas ; Roche, Bruno ; Mustafa, Mohammad Zahid ; Guettier, Catherine ; Johanet, Catherine ; Samuel, Didier ; Bouhris, Jean‐Henri ; Duclos‐Vallee, Jean‐Charles ; Ballot, Eric</creatorcontrib><description>The development of potentially severe non‐graft‐versus‐host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported after bone marrow transplantation (BMT). The aim of this study was to better characterize this form of hepatitis, particularly through the identification of autoantigens recognized by patient sera. Five patients who received an allogeneic BMT for the treatment of hematological diseases developed liver dysfunction with histological features suggestive of AIH. Before and during the onset of hepatic dysfunction, sera were tested on immunoblottings performed with cytosolic, microsomal, mitochondrial, and nuclear proteins from rat liver homogenate and resolved by two‐dimensional electrophoresis. Antigenic targets were identified by mass spectrometry. During the year that followed BMT, all patients presented with GVHD. Acute hepatitis then occurred after the withdrawal, or during the tapering, of immunosuppressive therapy. At that time, no patients had a history of liver toxic drug absorption, patent viral infection, or any histopathological findings consistent with GVHD. Immunoreactive spots stained by sera collected at the time of hepatic dysfunction were more numerous and more intensely expressed than those stained by sera collected before. Considerable patient‐dependent pattern heterogeneity was observed. Among the 259 spots stained exclusively by sera collected at the time of hepatitis, a total of 240 spots were identified, corresponding to 103 different proteins. Twelve of them were recognized by sera from 3 patients. Conclusions: This is the first immunological description of potentially severe non‐GVHD hepatitis occurring after BMT, determined using a proteomic approach and enabling a discussion of the mechanisms that transform an alloimmune reaction into an autoimmune response. Any decision to withdraw immunosuppression after allogeneic BMT should be made with caution. (HEPATOLOGY 2013)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.26024</identifier><identifier>PMID: 22911395</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Animals ; Bone marrow ; Bone Marrow Transplantation - adverse effects ; Chemical Sciences ; Female ; Graft vs Host Disease - etiology ; Graft vs Host Disease - immunology ; Hepatitis, Autoimmune - etiology ; Hepatitis, Autoimmune - immunology ; Hepatology ; Humans ; Male ; Middle Aged ; Organic chemistry ; Patients ; Proteins ; Proteomics ; Rats ; Transplantation, Homologous - immunology ; Transplants &amp; implants</subject><ispartof>Hepatology (Baltimore, Md.), 2013-02, Vol.57 (2), p.689-699</ispartof><rights>Copyright © 2012 American Association for the Study of Liver Diseases</rights><rights>Copyright © 2012 American Association for the Study of Liver Diseases.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4224-9e80f8bd1b9ed84527a332c2a5366a41b269ab5dc576930a6830c587a8d7113c3</citedby><cites>FETCH-LOGICAL-c4224-9e80f8bd1b9ed84527a332c2a5366a41b269ab5dc576930a6830c587a8d7113c3</cites><orcidid>0000-0003-0791-5505</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.26024$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.26024$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22911395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00798265$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Beleoken, Elvire</creatorcontrib><creatorcontrib>Sobesky, Rodolphe</creatorcontrib><creatorcontrib>Le Caer, Jean‐Pierre</creatorcontrib><creatorcontrib>Le Naour, François</creatorcontrib><creatorcontrib>Sebagh, Mylène</creatorcontrib><creatorcontrib>Moniaux, Nicolas</creatorcontrib><creatorcontrib>Roche, Bruno</creatorcontrib><creatorcontrib>Mustafa, Mohammad Zahid</creatorcontrib><creatorcontrib>Guettier, Catherine</creatorcontrib><creatorcontrib>Johanet, Catherine</creatorcontrib><creatorcontrib>Samuel, Didier</creatorcontrib><creatorcontrib>Bouhris, Jean‐Henri</creatorcontrib><creatorcontrib>Duclos‐Vallee, Jean‐Charles</creatorcontrib><creatorcontrib>Ballot, Eric</creatorcontrib><title>Immunoproteomic Analysis of Potentially Severe Non‐Graft‐Versus‐Host Disease Hepatitis After Allogenic Bone Marrow Transplantation</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>The development of potentially severe non‐graft‐versus‐host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported after bone marrow transplantation (BMT). The aim of this study was to better characterize this form of hepatitis, particularly through the identification of autoantigens recognized by patient sera. Five patients who received an allogeneic BMT for the treatment of hematological diseases developed liver dysfunction with histological features suggestive of AIH. Before and during the onset of hepatic dysfunction, sera were tested on immunoblottings performed with cytosolic, microsomal, mitochondrial, and nuclear proteins from rat liver homogenate and resolved by two‐dimensional electrophoresis. Antigenic targets were identified by mass spectrometry. During the year that followed BMT, all patients presented with GVHD. Acute hepatitis then occurred after the withdrawal, or during the tapering, of immunosuppressive therapy. At that time, no patients had a history of liver toxic drug absorption, patent viral infection, or any histopathological findings consistent with GVHD. Immunoreactive spots stained by sera collected at the time of hepatic dysfunction were more numerous and more intensely expressed than those stained by sera collected before. Considerable patient‐dependent pattern heterogeneity was observed. Among the 259 spots stained exclusively by sera collected at the time of hepatitis, a total of 240 spots were identified, corresponding to 103 different proteins. Twelve of them were recognized by sera from 3 patients. Conclusions: This is the first immunological description of potentially severe non‐GVHD hepatitis occurring after BMT, determined using a proteomic approach and enabling a discussion of the mechanisms that transform an alloimmune reaction into an autoimmune response. Any decision to withdraw immunosuppression after allogeneic BMT should be made with caution. (HEPATOLOGY 2013)</description><subject>Adult</subject><subject>Animals</subject><subject>Bone marrow</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>Chemical Sciences</subject><subject>Female</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - immunology</subject><subject>Hepatitis, Autoimmune - etiology</subject><subject>Hepatitis, Autoimmune - immunology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organic chemistry</subject><subject>Patients</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Rats</subject><subject>Transplantation, Homologous - immunology</subject><subject>Transplants &amp; implants</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1TAQhi1ERQ8tC14AWWLFIq0vudjLUEpT6RQq9bK1nGRCUzl2ajutzo4lS56RJ8HllLJiNaNfnz5p5kfoLSUHlBB2eAPzASsJy1-gFS1YlXFekJdoRVhFMkm53EWvQ7glhMiciVdolzFJU1ys0I_TaVqsm72L4Kaxw7XVZhPGgN2Az1No46iN2eALuAcP-Iuzv77_PPF6iGlegw9LSEvjQsSfxgA6AG5g1nGMyVEPETyujXHfwCb5R2cBn2nv3QO-9NqG2WgbE-zsPtoZtAnw5mnuoavPx5dHTbb-enJ6VK-zLmcszyQIMoi2p62EXuTpWM0565gueFnqnLaslLot-q6oSsmJLgUnXSEqLfoqndzxPfRh673RRs1-nLTfKKdH1dRr9ZgRUknByuKeJvb9lk3vuVsgRHXrFp8eFBRlIqdUcsr-GTvvQvAwPGspUY_9qNSP-tNPYt89GZd2gv6Z_FtIAg63wMNoYPN_k2qOz7fK351onRI</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Beleoken, Elvire</creator><creator>Sobesky, Rodolphe</creator><creator>Le Caer, Jean‐Pierre</creator><creator>Le Naour, François</creator><creator>Sebagh, Mylène</creator><creator>Moniaux, Nicolas</creator><creator>Roche, Bruno</creator><creator>Mustafa, Mohammad Zahid</creator><creator>Guettier, Catherine</creator><creator>Johanet, Catherine</creator><creator>Samuel, Didier</creator><creator>Bouhris, Jean‐Henri</creator><creator>Duclos‐Vallee, Jean‐Charles</creator><creator>Ballot, Eric</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wolters Kluwer Health, Inc</general><general>Wiley-Blackwell</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-0791-5505</orcidid></search><sort><creationdate>201302</creationdate><title>Immunoproteomic Analysis of Potentially Severe Non‐Graft‐Versus‐Host Disease Hepatitis After Allogenic Bone Marrow Transplantation</title><author>Beleoken, Elvire ; Sobesky, Rodolphe ; Le Caer, Jean‐Pierre ; Le Naour, François ; Sebagh, Mylène ; Moniaux, Nicolas ; Roche, Bruno ; Mustafa, Mohammad Zahid ; Guettier, Catherine ; Johanet, Catherine ; Samuel, Didier ; Bouhris, Jean‐Henri ; Duclos‐Vallee, Jean‐Charles ; Ballot, Eric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4224-9e80f8bd1b9ed84527a332c2a5366a41b269ab5dc576930a6830c587a8d7113c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Bone marrow</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>Chemical Sciences</topic><topic>Female</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - immunology</topic><topic>Hepatitis, Autoimmune - etiology</topic><topic>Hepatitis, Autoimmune - immunology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organic chemistry</topic><topic>Patients</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Rats</topic><topic>Transplantation, Homologous - immunology</topic><topic>Transplants &amp; implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beleoken, Elvire</creatorcontrib><creatorcontrib>Sobesky, Rodolphe</creatorcontrib><creatorcontrib>Le Caer, Jean‐Pierre</creatorcontrib><creatorcontrib>Le Naour, François</creatorcontrib><creatorcontrib>Sebagh, Mylène</creatorcontrib><creatorcontrib>Moniaux, Nicolas</creatorcontrib><creatorcontrib>Roche, Bruno</creatorcontrib><creatorcontrib>Mustafa, Mohammad Zahid</creatorcontrib><creatorcontrib>Guettier, Catherine</creatorcontrib><creatorcontrib>Johanet, Catherine</creatorcontrib><creatorcontrib>Samuel, Didier</creatorcontrib><creatorcontrib>Bouhris, Jean‐Henri</creatorcontrib><creatorcontrib>Duclos‐Vallee, Jean‐Charles</creatorcontrib><creatorcontrib>Ballot, Eric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beleoken, Elvire</au><au>Sobesky, Rodolphe</au><au>Le Caer, Jean‐Pierre</au><au>Le Naour, François</au><au>Sebagh, Mylène</au><au>Moniaux, Nicolas</au><au>Roche, Bruno</au><au>Mustafa, Mohammad Zahid</au><au>Guettier, Catherine</au><au>Johanet, Catherine</au><au>Samuel, Didier</au><au>Bouhris, Jean‐Henri</au><au>Duclos‐Vallee, Jean‐Charles</au><au>Ballot, Eric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoproteomic Analysis of Potentially Severe Non‐Graft‐Versus‐Host Disease Hepatitis After Allogenic Bone Marrow Transplantation</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2013-02</date><risdate>2013</risdate><volume>57</volume><issue>2</issue><spage>689</spage><epage>699</epage><pages>689-699</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>The development of potentially severe non‐graft‐versus‐host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported after bone marrow transplantation (BMT). The aim of this study was to better characterize this form of hepatitis, particularly through the identification of autoantigens recognized by patient sera. Five patients who received an allogeneic BMT for the treatment of hematological diseases developed liver dysfunction with histological features suggestive of AIH. Before and during the onset of hepatic dysfunction, sera were tested on immunoblottings performed with cytosolic, microsomal, mitochondrial, and nuclear proteins from rat liver homogenate and resolved by two‐dimensional electrophoresis. Antigenic targets were identified by mass spectrometry. During the year that followed BMT, all patients presented with GVHD. Acute hepatitis then occurred after the withdrawal, or during the tapering, of immunosuppressive therapy. At that time, no patients had a history of liver toxic drug absorption, patent viral infection, or any histopathological findings consistent with GVHD. Immunoreactive spots stained by sera collected at the time of hepatic dysfunction were more numerous and more intensely expressed than those stained by sera collected before. Considerable patient‐dependent pattern heterogeneity was observed. Among the 259 spots stained exclusively by sera collected at the time of hepatitis, a total of 240 spots were identified, corresponding to 103 different proteins. Twelve of them were recognized by sera from 3 patients. Conclusions: This is the first immunological description of potentially severe non‐GVHD hepatitis occurring after BMT, determined using a proteomic approach and enabling a discussion of the mechanisms that transform an alloimmune reaction into an autoimmune response. Any decision to withdraw immunosuppression after allogeneic BMT should be made with caution. (HEPATOLOGY 2013)</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22911395</pmid><doi>10.1002/hep.26024</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0791-5505</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2013-02, Vol.57 (2), p.689-699
issn 0270-9139
1527-3350
language eng
recordid cdi_hal_primary_oai_HAL_hal_00798265v1
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals
subjects Adult
Animals
Bone marrow
Bone Marrow Transplantation - adverse effects
Chemical Sciences
Female
Graft vs Host Disease - etiology
Graft vs Host Disease - immunology
Hepatitis, Autoimmune - etiology
Hepatitis, Autoimmune - immunology
Hepatology
Humans
Male
Middle Aged
Organic chemistry
Patients
Proteins
Proteomics
Rats
Transplantation, Homologous - immunology
Transplants & implants
title Immunoproteomic Analysis of Potentially Severe Non‐Graft‐Versus‐Host Disease Hepatitis After Allogenic Bone Marrow Transplantation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A34%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoproteomic%20Analysis%20of%20Potentially%20Severe%20Non%E2%80%90Graft%E2%80%90Versus%E2%80%90Host%20Disease%20Hepatitis%20After%20Allogenic%20Bone%20Marrow%20Transplantation&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Beleoken,%20Elvire&rft.date=2013-02&rft.volume=57&rft.issue=2&rft.spage=689&rft.epage=699&rft.pages=689-699&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.26024&rft_dat=%3Cproquest_hal_p%3E2883105131%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1284119312&rft_id=info:pmid/22911395&rfr_iscdi=true